Witnessing the stock’s movement on the chart, on Thursday, GSK Plc ADR (NYSE: GSK) had a quiet start as it plunged -3.29% to $49.12, before settling in for the price of $50.79 at the close. Taking a more long-term approach, GSK posted a 52-week range of $32.38-$51.46.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -11.63%. Meanwhile, its Annual Earning per share during the time was -11.63%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 13.71%. This publicly-traded company’s shares outstanding now amounts to $2.02 billion, simultaneously with a float of $2.02 billion. The organization now has a market capitalization sitting at $99.08 billion.
GSK Plc ADR (GSK) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Drug Manufacturers – General industry. GSK Plc ADR’s current insider ownership accounts for 0.00%, in contrast to 19.29% institutional ownership. According to the most recent insider trade that took place on Dec 11 ’25, this organization’s 10% Owner bought 1,470,000 shares at the rate of 19.00, making the entire transaction reach 27,930,000 in total value, affecting insider ownership by 18,245,691.
GSK Plc ADR (GSK) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.27 per share during the current fiscal year.
GSK Plc ADR’s EPS increase for this current 12-month fiscal period is 13.71% and is forecasted to reach 4.90 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 10.04% through the next 5 years, which can be compared against the -11.63% growth it accomplished over the previous five years trading on the market.
GSK Plc ADR (NYSE: GSK) Trading Performance Indicators
Let’s observe the current performance indicators for GSK Plc ADR (GSK). It’s Quick Ratio in the last reported quarter now stands at 0.55. Alongside those numbers, its PE Ratio stands at $14.01, and its Beta score is 0.47. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.36. Similarly, its price to free cash flow for trailing twelve months is now 12.38.
In the same vein, GSK’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 3.51, a figure that is expected to reach 0.64 in the next quarter, and analysts are predicting that it will be 4.90 at the market close of one year from today.
